Research & Development: Page 26

  • IV infusion
    Image attribution tooltip
    Amornrat Phuchom via Getty Images
    Image attribution tooltip

    While CAR-T wait times remain ‘heartbreaking,’ researchers push for innovations that could help

    Facing an unprecedented manufacturing bottleneck, a new coalition is aiming to create the next generation of CAR-T therapies.

    By • Nov. 8, 2022
  • Rami Elghandour headshot
    Image attribution tooltip
    Permission granted by Rami Elghandour
    Image attribution tooltip
    Profile

    Chasing that ‘Time magazine cover potential’

    Rami Elghandour was already retired. Then CAR-T specialist Arcellx lured him back into the industry to try to change the world.

    By Alexandra Pecci • Nov. 8, 2022
  • digital pill Explore the Trendline➔
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Artificial intelligence & machine learning

    After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

    By PharmaVoice staff
  • MRI Brain scan
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    After numerous setbacks, here’s where the Huntington’s pipeline stands

    A look at emerging treatments and where there’s hope for patients.

    By Kelly Bilodeau • Nov. 7, 2022
  • nerve signals in brain
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Acumen cruises into the fast lane with novel Alzheimer’s treatment

    The company’s distinct amyloid-beta target, which just won a fast track designation, could give it an edge over the competition.

    By • Nov. 3, 2022
  • Cat
    Image attribution tooltip
    Christopher Furlong / Staff via Getty Images
    Image attribution tooltip

    ‘Zombie’ cells, Shkreli and cats — new research in toxoplasmosis and how the three are connected

    Toxoplasmosis is carried by about a third of the world’s population, but effective drugs are lacking — now researchers have discovered a key infection element that could lead to better treatment.

    By • Nov. 3, 2022
  • diagram of man, doctor, phone, tablet
    Image attribution tooltip
    Retrieved from Google image.
    Image attribution tooltip

    While DCTs get all the hype, some industry insiders say the future is a digital hybrid

    Leaders at Veeva believe the wording around decentralized trials has been exaggerated, and that a bigger-picture outlook is important as the pandemic winds down.

    By • Nov. 1, 2022
  • tuberculosis scan
    Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip
    Q&A

    Tuberculosis patients haven’t seen new treatments in 40 years – now Merck and Gates MRI have teamed up to change that

    The Bill & Melinda Gates Medical Research Institute’s clinical development leader talks about its new licensing deal with Merck.

    By Alexandra Pecci • Nov. 1, 2022
  • A researcher with blue gloves holds a pipette tool in the right hand and a test tube in the left hand.
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Tips for tackling trial recruitment and retention woes in oncology

    How new tools are helping companies find and keep cancer patients in clinical studies.

    By Kelly Bilodeau • Oct. 31, 2022
  • Two researchers pipette blue liquid from beaker's to test tubes.
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    The first company to use Nobel-winning click chemistry in humans is on a mission to transform oncology

    Shasqi founder and CEO José Mejía Oneto on how the company’s approach could provide a more effective alternative to ADCs and other emerging cancer therapies.

    By Karissa Waddick • Oct. 27, 2022
  • A photo of Biogen's Alzheimer's drug Aduhelm
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip

    Riches, rags, riches: Is Biogen the Cinderella of biotechs?

    Biogen and Eisai's new Alzheimer's drug is wowing investigators, and it might help the companies get past previous failures.

    By • Oct. 27, 2022
  • Wearing a black hoodie, Carolyn Bertozzi stands in the forefront with a tan brick building blurred behind.
    Image attribution tooltip
    Justin Sullivan/Staff via Getty Images
    Image attribution tooltip
    Q&A

    Nobel Prize winner Carolyn Bertozzi on revealing the power of chemistry in drug development

    The Stanford researcher and biotech entrepreneur discusses how click and bioorthogonal chemistry could revolutionize drug development.

    By Karissa Waddick • Oct. 26, 2022
  • Tasuku Kitada head shot
    Image attribution tooltip
    Permission granted by Tasuku Kitada
    Image attribution tooltip
    Profile

    A longtime believer in mRNA, Strand Therapeutics’ co-founder is now pushing the tech to the next level

    The company’s co-founder and head of R&D on how it’s using synthetic mRNA to create “smarter” therapies that could provide cures for cancer and more.

    By Alexandra Pecci • Oct. 25, 2022
  • vial therapy
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Beyond cancer: Scientists push CAR-T cell therapies into new frontiers

    Why a ‘very exciting’ trial of the therapy in lupus patients could swing the door open to new studies in autoimmune diseases.

    By Kelly Bilodeau • Oct. 24, 2022
  • Insomnia in healthcare
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Opinion

    What’s keeping pharma leaders up at night

    C-suite execs in the life sciences share their late-night thoughts including innovation, patient access and market factors.

    By • Oct. 21, 2022
  • Wolly mammoth vintage
    Image attribution tooltip
    Stock illustration via Getty Images
    Image attribution tooltip
    Profile

    How a company aimed at bringing the woolly mammoth back to life spun off a startup that could speed drug development

    Colossal Biosciences announced the creation of Form Bio — and its “operating system for science” — in September.

    By Alexandra Pecci • Oct. 20, 2022
  • Charlotte Deane BW headshot
    Image attribution tooltip
    Diego Camargo/PharmaVoice
    Image attribution tooltip
    Podcast

    Woman of the Week: Exscientia’s Charlotte Deane

    Is the industry ready for a biologic discovery revolution? Charlotte Deane, chief scientist of biologics AI at Exscientia, thinks so.

    By • Oct. 19, 2022
  • missing target
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    5 impactful drug trial failures from the last year

    Major recent trial flops and what they mean for companies, patients and the industry.

    By • Oct. 19, 2022
  • Scientific illustration of a migrating breast cancer cell
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    A new class of drugs with ‘huge’ potential in the fight against challenging breast cancers

    Drug developers have been making headway in treating the most difficult and deadly forms of breast cancer.

    By Kelly Bilodeau • Oct. 18, 2022
  • black scientist
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The Novartis U.S. Foundation’s president on the ‘magical piece’ of its 10-year health equity plan

    Dr. Patrice Matchaba discusses Novartis’ end-to-end approach to tackling systemic health disparities.

    By • Oct. 17, 2022
  • Ryan Moslin, senior principal scientist, Bristol Myers Squibb
    Image attribution tooltip
    Permission granted by BMS / Ryan Moslin
    Image attribution tooltip
    Q&A

    He helped discover BMS’s psoriasis pill Sotyktu. Here’s what he has to say about early science in Big Pharma

    Bristol Myers Squibb’s senior principal scientist Ryan Moslin shares why his team was built for success and how they ushered a potential psoriasis blockbuster through discovery.

    By • Oct. 17, 2022
  • Medical professional in lab working on tablet.
    Image attribution tooltip
    Permission granted by Park & Battery
    Image attribution tooltip
    Sponsored by PPD

    Survey: The Top 5 Innovations and New Operational Strategies in Pharmaceutical R&D

    According to a recent survey conducted by PPD, part of Thermo Fisher Scientific, 98% of drug developers report that, in the wake of COVID-19, they have embraced a wealth of new strategies across the entire clinical trial lifecycle – from adaptive trial design to big data. Find out how to apply these trends to your innovative clinical programs.

    Oct. 17, 2022
  • woman checking her cell phone for provasic
    Image attribution tooltip
    Permission granted by GoodRx
    Image attribution tooltip
    Sponsored by GoodRx

    Does your copay program factor in differences across specialties? GoodRx analysis shows it should.

    New findings reveal an out-of-pocket cost gap between brand-name and generic prescriptions. To address this gap, GoodRx is partnering with pharmaceutical companies to improve cost transparency and communication between patients and providers.  

    Oct. 17, 2022
  • A wooden figurine of a business person sits at a higher spot on a table than a series of six other wooden figurines of business people.
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Making Moves

    BIO’s interim CEO and Alvotech’s new chief quality officer could spell big changes for biotech

    What these life science organizations’ latest executive-level appointments mean for the industry.

    By Karissa Waddick • Oct. 14, 2022
  • Subvariant virus spreading as viral pathogens
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Q&A // First 90 Days

    Coming out of stealth, RIGImmune aims to catch up with ever-mutating viruses

    President Susan Sobolov discusses how the startup is building on the work of two powerhouse Yale scientists to advance candidates for viruses — and beyond.

    By Kelly Bilodeau • Oct. 13, 2022
  • Green capsule medicine pill fall out of a production line.
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Robotic pills could open a world of possibilities for the biologics market

    As the oral biologic market heats up, Rani Therapeutics is looking to dominate the field with its robotic pill for treatment of chronic conditions. 

    By Karissa Waddick • Oct. 13, 2022